2025
Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
Gonzalez R, Horton R, Zhang X, Graham R, Longacre T, Mehrotra A, Allende D, McHugh K, Shia J, Westerhoff M, Srivastava A, Chen W, Vazzano J, Swanson P, Chatterjee D, Cheema H, Ma C, Mannan R, Chetty R, Nowak K, Serra S, Agostini‐Vulaj D, Kazemimood R, Henn P, Kakar S, Choi W, Adeyi O, Jenkins S, Nagtegaal I. Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects. Histopathology 2025 PMID: 39887413, DOI: 10.1111/his.15412.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesAdenosquamous carcinomaColorectal adenosquamous carcinomaTumor buddingPoor prognosisMedian time to progressionMeta-analysis of cohortLow tumor buddingTime to progressionMale:female ratioReview of casesIndividual case seriesNodal metastasisRecurrent diseaseSquamous componentPatient ageRecurrence rateAcademic medical centreCase seriesImmunohistochemical featuresPrognostic aspectsClinicopathological analysisFemale ratioFollow-upColorectal cancerThe evolving role of liver biopsy: Current applications and future prospects
Gopal P, Hu X, Robert M, Zhang X. The evolving role of liver biopsy: Current applications and future prospects. Hepatology Communications 2025, 9: e0628. PMID: 39774070, PMCID: PMC11717517, DOI: 10.1097/hc9.0000000000000628.Peer-Reviewed Original Research
2024
Hepatic Biliary Adenofibroma: Histological Characteristics, Diagnostic Challenges, and Its Role as a Precursor to Intrahepatic Cholangiocarcinoma
Liao X, Zhang X. Hepatic Biliary Adenofibroma: Histological Characteristics, Diagnostic Challenges, and Its Role as a Precursor to Intrahepatic Cholangiocarcinoma. Journal Of Clinical And Translational Pathology 2024, 4: 163-167. PMID: 40026322, PMCID: PMC11870646, DOI: 10.14218/jctp.2024.00044.Peer-Reviewed Original ResearchClinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes
Zhang T, Niu N, Taddei T, Jain D, Zhang X. Clinicopathologic features and prognosis of steatohepatitic hepatocellular carcinoma based on varying cutoffs of tumoral steatohepatitic changes. American Journal Of Clinical Pathology 2024, 163: 411-418. PMID: 39418121, DOI: 10.1093/ajcp/aqae136.Peer-Reviewed Original ResearchSH-HCCSteatohepatitic hepatocellular carcinomaHepatocellular carcinomaLiver diseaseHepatitis C virus infectionC virus infectionStage of fibrosisPresence of steatohepatitisOverall survivalHistological subtypesPrognostic factorsHCC subtypesBackground liverHCC casesClinicopathological featuresConventional HCCHistopathological patternsHyaline globulesTumor cellsMallory-Denk bodiesGlycogenated nucleiSteatotic liver diseaseHCCSurvival analysisSteatohepatitisHistologic Features of Mycobacterial Spindle Cell Pseudotumors
Szczepanski J, Lieberman J, Lamps L, Gonzalez R, Xue Y, Zhang X, Yilmaz O, Hart J, Krausz T, Mantilla J, McHugh J, Westerhoff M. Histologic Features of Mycobacterial Spindle Cell Pseudotumors. The American Journal Of Surgical Pathology 2024, 48: 890-900. PMID: 38726848, DOI: 10.1097/pas.0000000000002234.Peer-Reviewed Original ResearchConceptsMycobacterial spindle cell pseudotumorSpindle cell pseudotumorImmunocompromised patientsFoamy histiocytesLymph nodesNeutrophilic inflammationNeutrophilic microabscessesEvaluated lymph nodesComposition of inflammatory infiltratesSpindle cell neoplasmSecondary to infectionNon-tuberculous mycobacteriaArchitectural growth patternAcid-fast stainingMultinucleated giant cellsPeripheral granulomaSurgical therapyCell neoplasmsStromal changesHistological factorsSpindle cellsLymphocytic inflammationMicrobiological findingsClinical historyInflammatory infiltrateArtificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations
Jiao J, Tang H, Sun N, Zhang X. Artificial intelligence–aided steatosis assessment in donor livers according to the Banff consensus recommendations. American Journal Of Clinical Pathology 2024, 162: 401-407. PMID: 38716796, DOI: 10.1093/ajcp/aqae053.Peer-Reviewed Original ResearchBanff Working GroupLiver Allograft PathologyBiopsy specimensDonor liversAllograft pathologyAssociated with primary graft dysfunctionMacrovesicular steatosisPrimary graft dysfunctionManual quantificationSteatosis assessmentLiver biopsy specimensSevere macrovesicular steatosisAssessment of liver steatosisGraft dysfunctionPathological evaluationModerate steatosisEvaluate steatosisConsensus recommendationsLiver steatosisSteatosisBanffLiverPathologyAI modelsArtificial intelligence
2023
Colorectal Carcinoma With Sarcomatoid Components
Golconda U, McHugh K, Allende D, Collins K, Henn P, Lacambra M, Bejarano P, Groisman G, Loughrey M, Monappa V, Zhang X, Hornick J, Gonzalez R. Colorectal Carcinoma With Sarcomatoid Components. The American Journal Of Surgical Pathology 2023, 48: 465-474. PMID: 38155543, DOI: 10.1097/pas.0000000000002172.Peer-Reviewed Original ResearchConceptsSarcomatoid componentColorectal carcinomaUndifferentiated carcinomaTumor-infiltrating lymphocytesNodal metastasisAbdominal painDistant metastasisRare subtypeSMARCA4 lossTumor buddingHeterologous elementsRepair protein expressionRectosigmoid regionSpindle cellsGastrointestinal bleedingKeratin-positivePoor prognosisFollow-upCarcinomaMismatch repair protein expressionMolecular testingAdvanced stageTumorLoss of mismatch repair protein expressionProtein expressionLysophosphatidic acid triggers inflammation in the liver and white adipose tissue in rat models of 1-acyl-sn-glycerol-3-phosphate acyltransferase 2 deficiency and overnutrition
Sakuma I, Gaspar R, Luukkonen P, Kahn M, Zhang D, Zhang X, Murray S, Golla J, Vatner D, Samuel V, Petersen K, Shulman G. Lysophosphatidic acid triggers inflammation in the liver and white adipose tissue in rat models of 1-acyl-sn-glycerol-3-phosphate acyltransferase 2 deficiency and overnutrition. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2312666120. PMID: 38127985, PMCID: PMC10756285, DOI: 10.1073/pnas.2312666120.Peer-Reviewed Original ResearchDetection of Large-Droplet Macrovesicular Steatosis in Donor Livers Based on Segment-Anything Model
Tang H, Jiao J, Lin J, Zhang X, Sun N. Detection of Large-Droplet Macrovesicular Steatosis in Donor Livers Based on Segment-Anything Model. Laboratory Investigation 2023, 104: 100288. PMID: 37977550, DOI: 10.1016/j.labinv.2023.100288.Peer-Reviewed Original ResearchLiver diseaseMacrovesicular steatosisArtificial intelligence algorithmsArtificial intelligence modelsEnd-stage liver diseaseRule-based algorithmLiver histology analysisLiver transplant complicationsAcute liver failurePrimary hepatic malignancyLarge fat vacuolesIntelligence algorithmsDetection modelTransformer architectureIntelligence modelsTransplant complicationsLiver transplantationLiver failureLiver biopsyHepatic malignanciesFat vacuolesDonor organsEffective treatmentPrior knowledgeAlgorithmHistology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study
Hou T, Yang Z, Zhang Q, Zhang X, Liao X, Lin J. Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study. International Journal Of Surgical Pathology 2023, 32: 920-925. PMID: 37899731, DOI: 10.1177/10668969231208029.Peer-Reviewed Original ResearchNeoadjuvant therapyEsophageal adenocarcinomaNeuroendocrine neoplasmsNeuroendocrine carcinomaSurvival rateOverall median survival timeEsophageal neuroendocrine carcinomaPreoperative neoadjuvant therapyAdvanced esophageal adenocarcinomaMedian survival timeObserved survival ratesMainstay treatmentResidual adenocarcinomaConventional adenocarcinomaEsophageal cancerNeuroendocrine morphologyFocal positivitySurvival timeNeuroendocrine componentAdenocarcinomaBiopsyResectionSmall seriesPatientsNeoplasmsLet-7 suppresses liver fibrosis by inhibiting hepatocyte apoptosis and TGF-β production
Song J, Lv H, Liu B, Hao M, Taylor H, Zhang X, Li D, Huang Y. Let-7 suppresses liver fibrosis by inhibiting hepatocyte apoptosis and TGF-β production. Molecular Metabolism 2023, 78: 101828. PMID: 37898449, PMCID: PMC10641683, DOI: 10.1016/j.molmet.2023.101828.Peer-Reviewed Original ResearchConceptsFas-mediated apoptosisLet-7Hepatocyte apoptosisNegative feedback loopMouse primary hepatocytesLet-7 miRNAsTGF-b signalingSignaling networksApoptosis of hepatocytesTransient transfectionFas expressionInhibiting hepatocyte apoptosisSiRNA knockdownLet-7 expressionLet-7 overexpressionMouse modelApoptosisPrimary hepatocytesSuppressed hepatocyte apoptosisTET3Liver fibrosisFeedback loopExpressionDriver of liver fibrosisAdeno-associated viral vectorsThe Sympathetic Nervous System Promotes Hepatic Lymphangiogenesis, which Is Protective Against Liver Fibrosis
Tanaka M, Jeong J, Thomas C, Zhang X, Zhang P, Saruwatari J, Kondo R, McConnell M, Utsumi T, Iwakiri Y. The Sympathetic Nervous System Promotes Hepatic Lymphangiogenesis, which Is Protective Against Liver Fibrosis. American Journal Of Pathology 2023, 193: 2182-2202. PMID: 37673329, PMCID: PMC10699132, DOI: 10.1016/j.ajpath.2023.08.004.Peer-Reviewed Original ResearchConceptsPartial portal vein ligationNoncirrhotic portal hypertensionCirrhotic patientsVascular endothelial growth factorLiver fibrosisEndothelial growth factorPortal hypertensionSympathetic denervationSympathetic nervesBDL ratsVascular diseaseIdiopathic noncirrhotic portal hypertensionGrowth factorPortal hypertensive patientsPortal vein ligationSympathetic nervous systemMechanisms of lymphangiogenesisCeliac ganglionectomyHypertensive patientsLymphatic vessel numberLiver biopsyLiver cirrhosisVein ligationPPVL ratsHepatic lymphatic vesselsAn optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver
Jeong J, Tanaka M, Yang Y, Arefyev N, DiRito J, Tietjen G, Zhang X, McConnell M, Utsumi T, Iwakiri Y. An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver. AJP Gastrointestinal And Liver Physiology 2023, 325: g379-g390. PMID: 37605828, PMCID: PMC10887843, DOI: 10.1152/ajpgi.00139.2023.Peer-Reviewed Original ResearchPostinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases
Jiao J, Chezar K, Zhang X, Wang D, Cao W, Bindu C, Chen W, Neto A, Henn P, Riahi I, Wang H, Papke D, Zhao L, Xue Y, Liao X, Zhang X. Postinfantile Giant Cell Hepatitis in Native and Allograft Livers: A Multi-Institutional Clinicopathologic Study of 70 Cases. Modern Pathology 2023, 36: 100298. PMID: 37544363, DOI: 10.1016/j.modpat.2023.100298.Peer-Reviewed Original ResearchConceptsPostinfantile giant cell hepatitisAutoimmune liver diseaseGiant cell hepatitisAlkaline phosphatase levelsClinical outcomesPhosphatase levelsLiver diseaseMulti-institutional retrospective studyAssociated with better survivalAssociated with poor survivalClinicopathological characteristics of patientsAdverse prognostic factorAssociated with autoimmune liver diseasesGiant cellsVariable clinical outcomesFollow-up resultsCharacteristics of patientsDistribution of giant cellsOlder ageLiver disease etiologyPrognostic factorsAdvanced fibrosisBetter survivalClinicopathological characteristicsLiver allograftsSolid-Tubulocystic carcinoma: A new variant of intrahepatic cholangiocarcinoma
González I, Luo W, Zhang X. Solid-Tubulocystic carcinoma: A new variant of intrahepatic cholangiocarcinoma. World Journal Of Hepatology 2023, 15: 897-903. PMID: 37547028, PMCID: PMC10401414, DOI: 10.4254/wjh.v15.i7.897.Peer-Reviewed Original ResearchVariant of intrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaExpression of inhibinMetastatic hepatic neoplasmsCystic growth patternDiagnostic work-upRecurrent gene fusionsModerate amount of eosinophilic cytoplasmGene fusionsAmount of eosinophilic cytoplasmImmunohistochemical profileClinicopathological featuresEosinophilic cytoplasmBiliary markersTumor cellsMorphologic spectrumHepatic massHepatic neoplasmsWork-upHepatic carcinomaVariantsYoung womenInhibinTumorCholangiocarcinomaCholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P, Robert M, Zhang X. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine. Archives Of Pathology & Laboratory Medicine 2023, 148: 359-370. PMID: 37327187, DOI: 10.5858/arpa.2022-0537-ra.Peer-Reviewed Original ResearchConceptsDiagnosis of cholangiocarcinomaImmune checkpoint inhibitorsAdvanced tumor stageHeterogeneous tumor groupTumor growth patternEra of precision medicineTherapeutic decision-makingEvaluation of cholangiocarcinomaExtrahepatic biliary treeGenetic testing methodologiesSite of originCheckpoint inhibitorsTumor inaccessibilityMetastatic adenocarcinomaPeriductal infiltrationTumor stageIntraductal tumorClinical presentationDifferentiate cholangiocarcinomaImmunohistochemical profileTumor groupExtrahepatic cholangiocarcinomaTargeted therapyPathological diagnosisIntrahepatic cholangiocarcinomaClinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience
González I, Torbenson M, Sharifai N, Byrnes K, Chatterjee D, Kakar S, Yeh M, Wu T, Zhang X, Jain D. Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience. Human Pathology 2023, 138: 24-33. PMID: 37245629, DOI: 10.1016/j.humpath.2023.05.010.Peer-Reviewed Original ResearchConceptsHepatocellular adenomaHepatocellular carcinomaMalignant transformationMulticenter experienceMean ageWorld Health Organization classificationConcomitant hepatocellular carcinomaAndrogen receptor expressionBenign liver neoplasmUnclassified hepatocellular adenomaUncertain malignant potentialInflammatory hepatocellular adenomaΒ-catenin-activated hepatocellular adenomaClinicopathologic characterizationEntire cohortHCA casesCommon subtypeMalignant potentialOrganization classificationReproductive ageAllred score systemResection casesReceptor expressionHepatocellular neoplasmsLiver neoplasmsMulti-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer
Fernandez A, Robbins C, Gaule P, Agostini-Vulaj D, Anders R, Bellizzi A, Chen W, Chen Z, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan Y, Weidler J, Bates M, Zhang X, Rimm D. Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer. Modern Pathology 2023, 36: 100128. PMID: 36889057, PMCID: PMC10198879, DOI: 10.1016/j.modpat.2023.100128.Peer-Reviewed Original ResearchConceptsOverall percent agreementCut pointsReal-world settingHigher cut pointsCell death ligand 1Percent agreementGastroesophageal junction cancerPD-L1 immunohistochemistryDeath ligand 1Companion diagnostic testsMessenger RNA measurementsJunction cancerCancer casesImmunohistochemistry assaysIHC resultsDrug AdministrationPredictive valueScoring systemRange of assaysDiagnostic testsInstitutional studyRNA measurementsImmunohistochemistryPoor specificityPathologist's readingInhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
Luukkonen P, Sakuma I, Gaspar R, Mooring M, Nasiri A, Kahn M, Zhang X, Zhang D, Sammalkorpi H, Penttilä A, Orho-Melander M, Arola J, Juuti A, Zhang X, Yimlamai D, Yki-Järvinen H, Petersen K, Shulman G. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2217543120. PMID: 36669104, PMCID: PMC9942818, DOI: 10.1073/pnas.2217543120.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseLiver fibrosisLiver diseaseCommon chronic liver diseaseChronic liver diseaseFatty liver diseaseRisk of fibrosisDistinct mouse modelsPyrimidine catabolismNonalcoholic steatohepatitisMouse modelTherapeutic targetFibrosisDihydropyrimidine dehydrogenaseHuman liverA variantCommon variantsMetabolomics approachDiseaseMiceInhibitionCatabolismKnockdownSteatohepatitisGimeracil
2022
Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver
Santana J, Shewarega A, Nam D, Kahl V, Madoff D, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 404-408.e1. PMID: 36473611, PMCID: PMC11037556, DOI: 10.1016/j.jvir.2022.11.026.Peer-Reviewed Original ResearchConceptsLiver cirrhosisMale New Zealand white rabbitsRabbit liver tumor modelCirrhotic liver backgroundReproducible tumor growthVX2 liver cancerLeft hepatic lobeNew Zealand white rabbitsDuration of treatmentLiver tumor modelCross-sectional imagingVX2 rabbit liver tumor modelZealand white rabbitsHepatic lobeHistopathological evaluationMajor underlying factorHepatic tumorsIntragastric administrationHepatocellular carcinomaLiver tumorsLiver cancerCirrhosisUnmet needTumor growthVX2 tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply